autoimmune

Symbiotix Biotherapies, Inc. (“Symbiotix”), a pioneering venture-backed microbiome company developing novel molecular therapeutics based on the human microbiome, today announced that it has entered into a license agreement with Harvard University. Under the agreement, Symbiotix […]